Search Results for 'Ifn-Rbv'

Ifn-Rbv published presentations and documents on DocSlides.

SMV 12W + PEG-IFN + RBV 24-48W **

SMV 12W + PEG-IFN + RBV 24-48W **

by alexa-scheidler

SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...

by debby-jeon

SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....

Are (exogenous) interferons

Are (exogenous) interferons

by amey

really necessary?. Peter . Ferenci. Medical Univer...

by myesha-ticknor

Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...

by pasty-toler

Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...

Reddy KR. Lancet Infect Dis. 2015;15:27-35

Reddy KR. Lancet Infect Dis. 2015;15:27-35

by natalia-silvester

ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

by UnicornLove

C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...

Daclatasvir + Sofosbuvir + RBV in GT3

Daclatasvir + Sofosbuvir + RBV in GT3

by sophia2

. with Advanced Liver Disease. ALLY-3+ Study. Phas...

PEG alfa-2a RBV versus

PEG alfa-2a RBV versus

by alexa-scheidler

. PEG alfa-. 2a . versus. INF RBV . APRICOT S...

SOF + EBR + GZR + RBV

SOF + EBR + GZR + RBV

by test

N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...

by min-jolicoeur

Randomisation. Open-label. W8. * Liver biopsy or ...

FISSION Design Objective

FISSION Design Objective

by travis

Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...

Updated Guidelines for Managing HIV/HCV Co-Infection

Updated Guidelines for Managing HIV/HCV Co-Infection

by karlyn-bohler

John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...

by marina-yarberry

OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...

Hepatitis C Drug Pipeline

Hepatitis C Drug Pipeline

by cheryl-pisano

HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...

Direct Acting Antivirals: What are they? What is their pl

Direct Acting Antivirals: What are they? What is their pl

by tawny-fly

Mark Sulkowski, MD. Associate Professor of Medici...

David Fletcher, MD

David Fletcher, MD

by tatiana-dople

Department of Medicine. University of Toronto. Co...

by celsa-spraggs

Morris Sherman MD . BCh. PhD FRCP(C) . Associate...

by natalia-silvester

OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...

Current strategies for the management of treatment naïve a

Current strategies for the management of treatment naïve a

by min-jolicoeur

Mark S. Sulkowski, MD. Medical Director, Viral He...

by aaron

W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...

IFN α Induces MDSC Maturation and Loss of Suppressive Function

IFN α Induces MDSC Maturation and Loss of Suppressive Function

by LaughsALot

®. Treatment of plasmacytoid dendritic cells with...

Inhaled IFN-α1b for RSV

Inhaled IFN-α1b for RSV

by priscilla

B. ronchiolitis. Kunling. Shen MD.. . President...

Pharmacometrics and Biostatistics Interactions at the FDA

Pharmacometrics and Biostatistics Interactions at the FDA

by byrne

Jeffry Florian, Ph.D.. Division of Pharmacometrics...

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

by badra

Duke University School of Medicine. Durham, North ...

How to optimize treatment of G1 patients?

How to optimize treatment of G1 patients?

by KissesForYou

Prof. G. K. K. Lau 2012. Standard of care (SOC) ...

NS5A and polymerase inhibitors

NS5A and polymerase inhibitors

by LoveBug

Mark Sulkowski, MD. Professor of Medicine. Johns H...

522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc

522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc

by daisy

B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...

M.W. Fried , 1 M. Buti,

M.W. Fried , 1 M. Buti,

by iamamercy

2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

by webraph

Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

by trish-goza

IAPAC African Regional Capacity-Building Hub. Bas...

Hepatitis C Imtiaz Alam, M.D.

Hepatitis C Imtiaz Alam, M.D.

by olivia-moreira

Medical Director, Austin Hepatitis Center. 1. Hep...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by myesha-ticknor

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

by danika-pritchard

IAPAC African Regional Capacity-Building Hub. Bas...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by cheryl-pisano

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Prevention strategies for HIV/HCV co infection

Prevention strategies for HIV/HCV co infection

by giovanna-bartolotta

Isabelle Andrieux-Meyer, MD. Médecins Sans Front...

Chronic hepatitis C: guidelines for screening and

Chronic hepatitis C: guidelines for screening and

by aaron

treatment. Lisa M. Glass, MD. Clinical Lecturer. ...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

by lois-ondreau

Sameh W. Boktor, MD, MPH. Medical Epidemiologist....

OBV/PTV/r DSV Open label

OBV/PTV/r DSV Open label

by kittie-lecroy

≥ 18 years. Chronic HCV infection. Genotype 1. ...

OBV/PTV/r DSV RBV OBV/PTV/r

OBV/PTV/r DSV RBV OBV/PTV/r

by ellena-manuel

DSV . placebo. Randomisation*. Partial blind. 1...